Literature DB >> 9021173

Survival of anti-Clostridium difficile bovine immunoglobulin concentrate in the human gastrointestinal tract.

C P Kelly1, S Chetham, S Keates, E F Bostwick, A M Roush, I Castagliuolo, J T LaMont, C Pothoulakis.   

Abstract

To be therapeutically active, oral hyperimmune bovine immunoglobulin concentrate (BIC) must survive its passage through the intestinal tract. This led us to study the gastrointestinal stability of orally administered BIC directed against Clostridium difficile toxins (BIC-C. difficile). BIC-C. difficile was stable at neutral pH in vitro but was degraded at low pH, particularly in the presence of pepsin. Healthy volunteers (n = 6) took BIC-C. difficile (45 or 8 g) as a single oral dose. Total bovine immunoglobulin G (IgG) and specific anti-C. difficile IgG were measured in the stool. BIC was given under the following conditions: in the fasting state, in the fed state, with antacid, during omeprazole therapy, or in enteric capsules (released at pH > 6). The mean fecal bovine IgG content of 3-day stool collections was similar in the fasting (536 mg; 3.8% of the ingested dose of BIC), fed (221 mg; 1.6%), and antacid (381 mg; 2.7%) groups. Omeprazole therapy was associated with increased fecal bovine IgG levels (1253 mg; 8.8%), but this difference did not reach statistical significance (P = 0.07). Administration of 8 g of BIC-C. difficile in enteric capsules resulted in substantially higher fecal bovine IgG levels (1,124 mg; 32.7% of the oral dose) than those obtained after administration of nonencapsulated BIC (22 MG; 0.6%; P = 0.004). An inverse relationship was noted between intestinal transit time and fecal bovine IgG content (R = 0.83; P = 0.04 [data from omeprazole group]). Filtrates of stool samples collected after oral administration of BIC-C. difficile neutralized the cytotoxicity of C. difficile toxins A and B, whereas control stool filtrates did not. Bovine colostral IgG undergoes partial degradation in the intestinal tract. Exposure to acidic gastric secretions and prolonged colonic transit may both contribute to IgG degradation. Nonetheless, humans taking BIC-C. difficile orally have neutralizing antitoxin activity in their stool.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9021173      PMCID: PMC163695     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

1.  Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate.

Authors:  D M Lyerly; E F Bostwick; S B Binion; T D Wilkins
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

2.  Nucleotide sequence of Clostridium difficile toxin B gene.

Authors:  L A Barroso; S Z Wang; C J Phelps; J L Johnson; T D Wilkins
Journal:  Nucleic Acids Res       Date:  1990-07-11       Impact factor: 16.971

3.  Passive immunisation of children with bovine colostrum containing antibodies to human rotavirus.

Authors:  G P Davidson; P B Whyte; E Daniels; K Franklin; H Nunan; P I McCloud; A G Moore; D J Moore
Journal:  Lancet       Date:  1989-09-23       Impact factor: 79.321

Review 4.  Clostridium difficile: its disease and toxins.

Authors:  D M Lyerly; H C Krivan; T D Wilkins
Journal:  Clin Microbiol Rev       Date:  1988-01       Impact factor: 26.132

5.  Treatment with bovine hyperimmune colostrum of cryptosporidial diarrhea in AIDS patients.

Authors:  J Nord; P Ma; D DiJohn; S Tzipori; C O Tacket
Journal:  AIDS       Date:  1990-06       Impact factor: 4.177

6.  Cloning of Clostridium difficile toxin B gene and demonstration of high N-terminal homology between toxin A and B.

Authors:  C von Eichel-Streiber; R Laufenberg-Feldmann; S Sartingen; J Schulze; M Sauerborn
Journal:  Med Microbiol Immunol       Date:  1990       Impact factor: 3.402

7.  Efficacy of bovine milk immunoglobulin concentrate in preventing illness after Shigella flexneri challenge.

Authors:  C O Tacket; S B Binion; E Bostwick; G Losonsky; M J Roy; R Edelman
Journal:  Am J Trop Med Hyg       Date:  1992-09       Impact factor: 2.345

8.  Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A.

Authors:  G Corthier; M C Muller; T D Wilkins; D Lyerly; R L'Haridon
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

9.  Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin.

Authors:  D Y Leung; C P Kelly; M Boguniewicz; C Pothoulakis; J T LaMont; A Flores
Journal:  J Pediatr       Date:  1991-04       Impact factor: 4.406

10.  Human colonic aspirates containing immunoglobulin A antibody to Clostridium difficile toxin A inhibit toxin A-receptor binding.

Authors:  C P Kelly; C Pothoulakis; J Orellana; J T LaMont
Journal:  Gastroenterology       Date:  1992-01       Impact factor: 22.682

View more
  23 in total

Review 1.  Passive immunity against human pathogens using bovine antibodies.

Authors:  C Weiner; Q Pan; M Hurtig; T Borén; E Bostwick; L Hammarström
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

Review 2.  Immune-based treatment and prevention of Clostridium difficile infection.

Authors:  Song Zhao; Chandrabali Ghose-Paul; Keshan Zhang; Saul Tzipori; Xingmin Sun
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

3.  Bovine immunoglobulin concentrate-clostridium difficile retains C difficile toxin neutralising activity after passage through the human stomach and small intestine.

Authors:  M Warny; A Fatimi; E F Bostwick; D C Laine; F Lebel; J T LaMont; C Pothoulakis; C P Kelly
Journal:  Gut       Date:  1999-02       Impact factor: 23.059

4.  Structural features of bovine colostral immunoglobulin that confer proteolytic stability in a simulated intestinal fluid.

Authors:  Randall E Burton; Skaison Kim; Rutvij Patel; Deborah S Hartman; Daniel E Tracey; Barbara S Fox
Journal:  J Biol Chem       Date:  2020-07-14       Impact factor: 5.157

5.  Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications.

Authors:  Ramsey M Dallal; Brian G Harbrecht; Arthur J Boujoukas; Carl A Sirio; Linda M Farkas; Kenneth K Lee; Richard L Simmons
Journal:  Ann Surg       Date:  2002-03       Impact factor: 12.969

6.  Hyperimmune bovine colostrum as a novel therapy to combat Clostridium difficile infection.

Authors:  Jerlyn K Sponseller; Jennifer A Steele; Diane J Schmidt; Hyeun Bum Kim; Gillian Beamer; Xingmin Sun; Saul Tzipori
Journal:  J Infect Dis       Date:  2014-11-07       Impact factor: 5.226

Review 7.  Breakthroughs in the treatment and prevention of Clostridium difficile infection.

Authors:  Larry K Kociolek; Dale N Gerding
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-02-10       Impact factor: 46.802

Review 8.  Update on Clostridium difficile infection.

Authors:  C S Alcantara; R L Guerrant
Journal:  Curr Gastroenterol Rep       Date:  2000-08

9.  Neutralization of Clostridium difficile Toxin B Mediated by Engineered Lactobacilli That Produce Single-Domain Antibodies.

Authors:  Kasper Krogh Andersen; Nika M Strokappe; Anna Hultberg; Kai Truusalu; Imbi Smidt; Raik-Hiio Mikelsaar; Marika Mikelsaar; Theo Verrips; Lennart Hammarström; Harold Marcotte
Journal:  Infect Immun       Date:  2015-11-16       Impact factor: 3.441

10.  New advances in the treatment of Clostridium difficile infection (CDI).

Authors:  Dennis D Hedge; Joe D Strain; Jodi R Heins; Debra K Farver
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.